Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...

Johnson & Johnson is a global leader in the pharmaceutical and medical device industries. Its key products include ...

For many readers, the topics featured in this year’s roundup of top stories won’t come as much of a surprise. Look no further than our top two stories of the year and you’ll see that the GLP-1 craze ...

A Sun Pharmaceutical Industries researcher at work. Sun Pharma has agreed to acquire Organon, the women’s health drug developer spun out of Merck & Co., for $11.75 billion in a deal intended to ...

While coming back down from 2023’s dizzying high, Merck & Co. still managed to hang on to the top spot of our annual R&D budgets in pharma list. Though Merck’s 2024 R&D spending plummeted by almost ...

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity ...

Pharma stocks have been on quite a nice run over the past year. A number of new catalysts have revitalized this sector, which I’m going to dive into with a few of these picks. Whether we’re talking ...